Skip to main content
Top
Published in: Diabetology & Metabolic Syndrome 1/2024

Open Access 01-12-2024 | Type 2 Diabetes | Research

Connections between body composition and dysregulation of islet α- and β-cells in type 2 diabetes

Authors: Jia-xi Miao, Jia-ping Xu, Rui Wang, Yu-xian Xu, Feng Xu, Chun-hua Wang, Chao Yu, Dong-mei Zhang, Jian-bin Su

Published in: Diabetology & Metabolic Syndrome | Issue 1/2024

Login to get access

Abstract

Background

Accompanying islet α- and β-cell dysregulation in type 2 diabetes (T2D) at the microscopic scale, alterations in body composition at the macroscopic scale may affect the pathogenesis of T2D. However, the connections between body composition and islet α-cell and β-cell functions in T2D have not been thoroughly explored.

Methods

For this cross-sectional study, we recruited a total of 729 Chinese Han patients with T2D in a consecutive manner. Dual-energy X-ray absorptiometry (DXA) was used to measure body composition, which included total bone-free mass, total fat and lean mass, trunk fat and lean mass and limb fat and lean mass. Every patient underwent an oral glucose tolerance test to simultaneously detect glucose, C-peptide and glucagon. The indices of islet α-cell function included fasting glucagon levels and the area under the curve of glucagon after a challenge (AUCglucagon), while the indices of β-cell function included the insulin sensitivity index derived from C-peptide (ISIC-peptide) and the area under the curve of C-peptide after a challenge (AUCC-peptide).

Results

Among all patients, fat mass, especially trunk fat mass, was significantly correlated with ISIC-peptide and AUCC-peptide levels (r = − 0.330 and 0.317, respectively, p < 0.001), while lean mass, especially limb lean mass, was significantly correlated with fasting glucagon and AUCglucagon levels (r = − 0.196 and − 0.214, respectively, p < 0.001). Moreover, after adjusting for other relevant variables via multivariate linear regression analysis, increased trunk fat mass was independently associated with decreased ISIC-peptide (β = − 0.247, t = − 3.628, p < 0.001, partial R2 = 10.9%) and increased AUCC-peptide (β = 0.229, t = 3.581, p < 0.001, partial R2 = 8.2%), while decreased limb lean mass was independently associated with increased fasting glucagon (β = − 0.226, t = − 2.127, p = 0.034, partial R2 = 3.8%) and increased AUCglucagon (β = − 0.218, t = − 2.050, p = 0.041, partial R2 = 2.3%). Additionally, when separate analyses were performed with the same concept for both sexes, we found that increased trunk fat mass was still independently associated with decreased ISIC-peptide and increased AUCC-peptide, while decreased limb lean mass was still independently associated with increased fasting glucagon and AUCglucagon.

Conclusions

Increased trunk fat mass may partly account for decreased insulin sensitivity and increased insulin secretion, while decreased limb lean mass may be connected to increased fasting glucagon and postprandial glucagon secretion.
Appendix
Available only for authorised users
Literature
1.
go back to reference Caruso I, Marrano N, Biondi G, Genchi VA, D’Oria R, Sorice GP, et al. Glucagon in type 2 diabetes: friend or foe? Diabetes Metab Res Rev. 2023;39(3): e3609.CrossRefPubMed Caruso I, Marrano N, Biondi G, Genchi VA, D’Oria R, Sorice GP, et al. Glucagon in type 2 diabetes: friend or foe? Diabetes Metab Res Rev. 2023;39(3): e3609.CrossRefPubMed
2.
go back to reference Rodriguez-Diaz R, Tamayo A, Hara M, Caicedo A. the local paracrine actions of the pancreatic α-cell. Diabetes. 2020;69(4):550–8.CrossRefPubMed Rodriguez-Diaz R, Tamayo A, Hara M, Caicedo A. the local paracrine actions of the pancreatic α-cell. Diabetes. 2020;69(4):550–8.CrossRefPubMed
4.
go back to reference Jain C, Bilekova S, Lickert H. Targeting pancreatic β cells for diabetes treatment. Nat Metab. 2022;4(9):1097–108.CrossRefPubMed Jain C, Bilekova S, Lickert H. Targeting pancreatic β cells for diabetes treatment. Nat Metab. 2022;4(9):1097–108.CrossRefPubMed
5.
go back to reference Park JH, Lee MY, Shin HK, Yoon KJ, Lee J, Park JH. Lower skeletal muscle mass is associated with diabetes and insulin resistance: a cross-sectional study. Diabetes Metab Res Rev. 2023;39(7): e3681.CrossRefPubMed Park JH, Lee MY, Shin HK, Yoon KJ, Lee J, Park JH. Lower skeletal muscle mass is associated with diabetes and insulin resistance: a cross-sectional study. Diabetes Metab Res Rev. 2023;39(7): e3681.CrossRefPubMed
6.
go back to reference Choi SI, Chung D, Lim JS, Lee MY, Shin JY, Chung CH, et al. relationship between regional body fat distribution and diabetes mellitus: 2008 to 2010 Korean National Health and Nutrition Examination Surveys. Diabetes Metab J. 2017;41(1):51–9.CrossRefPubMed Choi SI, Chung D, Lim JS, Lee MY, Shin JY, Chung CH, et al. relationship between regional body fat distribution and diabetes mellitus: 2008 to 2010 Korean National Health and Nutrition Examination Surveys. Diabetes Metab J. 2017;41(1):51–9.CrossRefPubMed
7.
go back to reference Vidmar AP, Durazo-Arvizu R, Weigensberg MJ, Alderete TL, Goran MI. Rapid decline in β-cell function and increasing adiposity are associated with conversion to type 2 diabetes in at-risk latino youth. Diabetes. 2023;72(6):735–45.CrossRefPubMed Vidmar AP, Durazo-Arvizu R, Weigensberg MJ, Alderete TL, Goran MI. Rapid decline in β-cell function and increasing adiposity are associated with conversion to type 2 diabetes in at-risk latino youth. Diabetes. 2023;72(6):735–45.CrossRefPubMed
8.
go back to reference Santhanam P, Rowe SP, Dias JP, Ahima RS. Relationship between DXA measured metrics of adiposity and glucose homeostasis; an analysis of the NHANES data. PLoS ONE. 2019;14(5): e0216900.CrossRefPubMedPubMedCentral Santhanam P, Rowe SP, Dias JP, Ahima RS. Relationship between DXA measured metrics of adiposity and glucose homeostasis; an analysis of the NHANES data. PLoS ONE. 2019;14(5): e0216900.CrossRefPubMedPubMedCentral
9.
go back to reference Anoop S, Misra A, Bhatt SP, Gulati S, Mahajan H, Prabakaran G. High plasma glucagon levels correlate with waist-to-hip ratio, suprailiac skinfold thickness, and deep subcutaneous abdominal and intraperitoneal adipose tissue depots in nonobese asian indian males with type 2 diabetes in north India. J Diabetes Res. 2017;2017:2376016.CrossRefPubMedPubMedCentral Anoop S, Misra A, Bhatt SP, Gulati S, Mahajan H, Prabakaran G. High plasma glucagon levels correlate with waist-to-hip ratio, suprailiac skinfold thickness, and deep subcutaneous abdominal and intraperitoneal adipose tissue depots in nonobese asian indian males with type 2 diabetes in north India. J Diabetes Res. 2017;2017:2376016.CrossRefPubMedPubMedCentral
10.
go back to reference Classification and Diagnosis of Diabetes. Standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S15–33. Classification and Diagnosis of Diabetes. Standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S15–33.
11.
go back to reference Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247–54.CrossRefPubMed Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247–54.CrossRefPubMed
12.
go back to reference Su JB, Wu YY, Xu F, Wang X, Cai HL, Zhao LH, et al. Serum complement C3 and islet β-cell function in patients with type 2 diabetes: A 4.6-year prospective follow-up study. Endocrine. 2020;67(2):321–30.CrossRefPubMed Su JB, Wu YY, Xu F, Wang X, Cai HL, Zhao LH, et al. Serum complement C3 and islet β-cell function in patients with type 2 diabetes: A 4.6-year prospective follow-up study. Endocrine. 2020;67(2):321–30.CrossRefPubMed
13.
go back to reference Radaelli T, Farrell KA, Huston-Presley L, Amini SB, Kirwan JP, McIntyre HD, et al. Estimates of insulin sensitivity using glucose and C-Peptide from the hyperglycemia and adverse pregnancy outcome glucose tolerance test. Diabetes Care. 2010;33(3):490–4.CrossRefPubMed Radaelli T, Farrell KA, Huston-Presley L, Amini SB, Kirwan JP, McIntyre HD, et al. Estimates of insulin sensitivity using glucose and C-Peptide from the hyperglycemia and adverse pregnancy outcome glucose tolerance test. Diabetes Care. 2010;33(3):490–4.CrossRefPubMed
14.
go back to reference Zhao L, Ma J, Wang S, Xie Y. Relationship between β-cell function, metabolic control, and microvascular complications in type 2 diabetes mellitus. Diabetes Technol Ther. 2015;17(1):29–34.CrossRefPubMed Zhao L, Ma J, Wang S, Xie Y. Relationship between β-cell function, metabolic control, and microvascular complications in type 2 diabetes mellitus. Diabetes Technol Ther. 2015;17(1):29–34.CrossRefPubMed
16.
go back to reference Xiang AH, Kawakubo M, Trigo E, Kjos SL, Buchanan TA. Declining beta-cell compensation for insulin resistance in Hispanic women with recent gestational diabetes mellitus: association with changes in weight, adiponectin, and C-reactive protein. Diabetes Care. 2010;33(2):396–401.CrossRefPubMed Xiang AH, Kawakubo M, Trigo E, Kjos SL, Buchanan TA. Declining beta-cell compensation for insulin resistance in Hispanic women with recent gestational diabetes mellitus: association with changes in weight, adiponectin, and C-reactive protein. Diabetes Care. 2010;33(2):396–401.CrossRefPubMed
17.
go back to reference Lotta LA, Gulati P, Day FR, Payne F, Ongen H, van de Bunt M, et al. Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance. Nat Genet. 2017;49(1):17–26.CrossRefPubMed Lotta LA, Gulati P, Day FR, Payne F, Ongen H, van de Bunt M, et al. Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance. Nat Genet. 2017;49(1):17–26.CrossRefPubMed
18.
go back to reference Alderete TL, Toledo-Corral CM, Goran MI. Metabolic basis of ethnic differences in diabetes risk in overweight and obese youth. Curr Diab Rep. 2014;14(2):455.CrossRefPubMedPubMedCentral Alderete TL, Toledo-Corral CM, Goran MI. Metabolic basis of ethnic differences in diabetes risk in overweight and obese youth. Curr Diab Rep. 2014;14(2):455.CrossRefPubMedPubMedCentral
19.
go back to reference Goran MI, Lane C, Toledo-Corral C, Weigensberg MJ. Persistence of pre-diabetes in overweight and obese Hispanic children: association with progressive insulin resistance, poor beta-cell function, and increasing visceral fat. Diabetes. 2008;57(11):3007–12.CrossRefPubMedPubMedCentral Goran MI, Lane C, Toledo-Corral C, Weigensberg MJ. Persistence of pre-diabetes in overweight and obese Hispanic children: association with progressive insulin resistance, poor beta-cell function, and increasing visceral fat. Diabetes. 2008;57(11):3007–12.CrossRefPubMedPubMedCentral
20.
go back to reference Sakai S, Tanimoto K, Imbe A, Inaba Y, Shishikura K, Tanimoto Y, et al. Decreased β-cell function is associated with reduced skeletal muscle mass in Japanese subjects without diabetes. PLoS ONE. 2016;11(9): e0162603.CrossRefPubMedPubMedCentral Sakai S, Tanimoto K, Imbe A, Inaba Y, Shishikura K, Tanimoto Y, et al. Decreased β-cell function is associated with reduced skeletal muscle mass in Japanese subjects without diabetes. PLoS ONE. 2016;11(9): e0162603.CrossRefPubMedPubMedCentral
21.
go back to reference Ma M, Jiang T, Wen Z, Zhang D, Xiu L. Gender differences in relation to body composition, insulin resistance, and islet beta cell function in newly diagnosed diabetic or pre-diabetic patients. Diabetes Metab Syndr Obes. 2023;16:723–32.CrossRefPubMedPubMedCentral Ma M, Jiang T, Wen Z, Zhang D, Xiu L. Gender differences in relation to body composition, insulin resistance, and islet beta cell function in newly diagnosed diabetic or pre-diabetic patients. Diabetes Metab Syndr Obes. 2023;16:723–32.CrossRefPubMedPubMedCentral
22.
go back to reference Chen MJ, Leng J, Ni JP, Xiong AL, Hu MY. U-shaped association between plasma c-peptide and sarcopenia: a cross-sectional study of elderly chinese patients with diabetes mellitus. PLoS ONE. 2023;18(10): e0292654.CrossRefPubMedPubMedCentral Chen MJ, Leng J, Ni JP, Xiong AL, Hu MY. U-shaped association between plasma c-peptide and sarcopenia: a cross-sectional study of elderly chinese patients with diabetes mellitus. PLoS ONE. 2023;18(10): e0292654.CrossRefPubMedPubMedCentral
23.
go back to reference Laurenti MC, Vella A, Adams JD, Schembri Wismayer DJ, Egan AM, Dalla MC. Assessment of individual and standardized glucagon kinetics in healthy humans. Am J Physiol Endocrinol Metab. 2021;320(1):E71–7.CrossRefPubMed Laurenti MC, Vella A, Adams JD, Schembri Wismayer DJ, Egan AM, Dalla MC. Assessment of individual and standardized glucagon kinetics in healthy humans. Am J Physiol Endocrinol Metab. 2021;320(1):E71–7.CrossRefPubMed
24.
go back to reference Færch K, Vistisen D, Pacini G, Torekov SS, Johansen NB, Witte DR, et al. Insulin resistance is accompanied by increased fasting glucagon and delayed glucagon suppression in individuals with normal and impaired glucose regulation. Diabetes. 2016;65(11):3473–81.CrossRefPubMed Færch K, Vistisen D, Pacini G, Torekov SS, Johansen NB, Witte DR, et al. Insulin resistance is accompanied by increased fasting glucagon and delayed glucagon suppression in individuals with normal and impaired glucose regulation. Diabetes. 2016;65(11):3473–81.CrossRefPubMed
26.
go back to reference Hædersdal S, Andersen A, Knop FK, Vilsbøll T. Revisiting the role of glucagon in health, diabetes mellitus and other metabolic diseases. Nat Rev Endocrinol. 2023;19(6):321–35.CrossRefPubMed Hædersdal S, Andersen A, Knop FK, Vilsbøll T. Revisiting the role of glucagon in health, diabetes mellitus and other metabolic diseases. Nat Rev Endocrinol. 2023;19(6):321–35.CrossRefPubMed
27.
go back to reference Miller RA, Birnbaum MJ. Glucagon: acute actions on hepatic metabolism. Diabetologia. 2016;59(7):1376–81.CrossRefPubMed Miller RA, Birnbaum MJ. Glucagon: acute actions on hepatic metabolism. Diabetologia. 2016;59(7):1376–81.CrossRefPubMed
28.
go back to reference Pedersen C, Porsgaard T, Thomsen M, Rosenkilde MM, Roed NK. Sustained effect of glucagon on body weight and blood glucose: assessed by continuous glucose monitoring in diabetic rats. PLoS ONE. 2018;13(3): e0194468.CrossRefPubMedPubMedCentral Pedersen C, Porsgaard T, Thomsen M, Rosenkilde MM, Roed NK. Sustained effect of glucagon on body weight and blood glucose: assessed by continuous glucose monitoring in diabetic rats. PLoS ONE. 2018;13(3): e0194468.CrossRefPubMedPubMedCentral
29.
go back to reference Ueno S, Seino Y, Hidaka S, Nakatani M, Hitachi K, Murao N, et al. Blockade of glucagon increases muscle mass and alters fiber type composition in mice deficient in proglucagon-derived peptides. J Diabetes Investig. 2023;14(9):1045–55.CrossRefPubMedPubMedCentral Ueno S, Seino Y, Hidaka S, Nakatani M, Hitachi K, Murao N, et al. Blockade of glucagon increases muscle mass and alters fiber type composition in mice deficient in proglucagon-derived peptides. J Diabetes Investig. 2023;14(9):1045–55.CrossRefPubMedPubMedCentral
30.
go back to reference Okun JG, Rusu PM, Chan AY, Wu Y, Yap YW, Sharkie T, et al. Liver alanine catabolism promotes skeletal muscle atrophy and hyperglycaemia in type 2 diabetes. Nat Metab. 2021;3(3):394–409.CrossRefPubMed Okun JG, Rusu PM, Chan AY, Wu Y, Yap YW, Sharkie T, et al. Liver alanine catabolism promotes skeletal muscle atrophy and hyperglycaemia in type 2 diabetes. Nat Metab. 2021;3(3):394–409.CrossRefPubMed
Metadata
Title
Connections between body composition and dysregulation of islet α- and β-cells in type 2 diabetes
Authors
Jia-xi Miao
Jia-ping Xu
Rui Wang
Yu-xian Xu
Feng Xu
Chun-hua Wang
Chao Yu
Dong-mei Zhang
Jian-bin Su
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2024
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/s13098-023-01250-3

Other articles of this Issue 1/2024

Diabetology & Metabolic Syndrome 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.